Vectura News Discover more about our company, science, innovation and people with the latest headlines from Vectura.
“Strategies for rapid progression of inhaled products” at Formulation & Delivery Europe Congress: Online Published15/04/2021 Read more
Vectura Expands Dry Powder Inhaler Development and Manufacturing Capabilities at its Facility in Chippenham, U.K. Published05/03/2021 Read more
Vectura Group appoints Jeanne Hecht and Jeanne Thoma to its Board of Directors Published30/12/2020 Read more
Vectura earns $11m milestone as Hikma receives US FDA approval for generic Advair Diskus® Published17/12/2020 Read more
Vectura Expands Capabilities to Handle and Develop Highly Potent Inhaled Drugs at its Facility in Chippenham, U.K. Published14/12/2020 Read more
Vectura signs agreement with Kinaset Therapeutics Inc. to support the development of VR588 to treat asthma Published30/11/2020 Read more
Will Downie’s podcast: “There’s a patient at the end of every piece of work we do…” Published08/10/2020 Read more
Vectura shortlisted for ’Excellence in Pharma: Contract Services and Outsourcing’ Published24/09/2020 Read more
Vectura partners with Monash University to support development of inhaled oxytocin to prevent postpartum haemorrhage Published14/09/2020 Read more
Live Webcast 24th June: Dry Powder Inhalers – Key Considerations for Combination Product Development Published17/06/2020 Read more
Vectura expands business development team with three global appointments Published03/06/2020 Read more
Sharon Johnson appointed Executive Vice President for Delivery Management Published10/02/2020 Read more
Pre-close trading update confirms 2019 trading in-line with expectations Published13/01/2020 Read more
Vectura to present latest science at Drug Delivery to the Lungs (DDL) 2019 Published22/10/2019 Read more
Vectura wins US GSK patent litigation and awarded $89.7m in damages by jury Published26/04/2019 Read more
Global agreement with Hikma to develop generic versions of GSK’s Ellipta® portfolio Published08/11/2018 Read more
